BofA lowered the firm’s price target on CG Oncology (CGON) to $62 from $63 and keeps a Buy rating on the shares post the Q2 report. The firm sees significant value generation opportunities for CG over the next 12-18. The company remains a frontrunner in the HR non-muscle invasive bladder cancer space, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology’s Q2 2025: Clinical Advances and Legal Wins
- Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements
- CG Oncology reports Q2 EPS (54c), consensus (44c)
- Positive Outlook for CG Oncology: Legal Victory and Promising Milestones Drive Buy Rating
- CG Oncology announces Delaware Superior Court ruling in its favor